Literature DB >> 9565212

Attitudes toward methadone maintenance: implications for HIV prevention.

W A Zule1, D P Desmond.   

Abstract

Attitudes of opioid users toward methadone maintenance were studied using semi-structured field interviews. One hundred and sixty-one heroin and speedball users in San Antonio, Texas, were interviewed between 1989 and 1992. Users were classified according to whether or not they had ever been on methadone maintenance. Opioid users who had never been on methadone maintenance were more likely to express a negative attitude toward methadone maintenance than users who had been on it (50% versus 30%). Sources of negative attitudes fell into the following categories: (1) general societal disapproval of addictive drugs, including methadone; (2) prior experience with 12 Step groups or abstinence-based treatment programs; (3) previous forced rapid detoxification from methadone in jail; and (4) observation of methadone maintained peers who continued to use drugs. Very few respondents reported adverse effects from methadone itself as a source of negative attitudes. Sources of positive attitudes included: (1) prior successful treatment with methadone; and (2) observation of methadone patients who stopped using drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9565212     DOI: 10.1080/02791072.1998.10399674

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  11 in total

1.  Beliefs about methadone in an inner-city methadone clinic.

Authors:  Sharon Stancliff; Julie Elana Myers; Stuart Steiner; Ernest Drucker
Journal:  J Urban Health       Date:  2002-12       Impact factor: 3.671

2.  Ethical and human rights imperatives to ensure medication-assisted treatment for opioid dependence in prisons and pre-trial detention.

Authors:  R Douglas Bruce; Rebecca A Schleifer
Journal:  Int J Drug Policy       Date:  2008-01-15

3.  Why don't out-of-treatment individuals enter methadone treatment programmes?

Authors:  James A Peterson; Robert P Schwartz; Shannon Gwin Mitchell; Heather Schacht Reisinger; Sharon M Kelly; Kevin E O'Grady; Barry S Brown; Michael H Agar
Journal:  Int J Drug Policy       Date:  2008-09-20

4.  Treatment readiness, attitudes toward, and experiences with methadone and buprenorphine maintenance therapy among people who inject drugs in Malaysia.

Authors:  Aishwarya Vijay; Alexander R Bazazi; Ilias Yee; Adeeba Kamarulzaman; Frederick L Altice
Journal:  J Subst Abuse Treat       Date:  2015-02-18

5.  Heroin-dependent inmates' experiences with buprenorphine or methadone maintenance.

Authors:  Ezechukwu Awgu; Stephen Magura; Andrew Rosenblum
Journal:  J Psychoactive Drugs       Date:  2010-09

6.  The trouble with morality: the effects of 12-step discourse on addicts' decision-making.

Authors:  David Frank
Journal:  J Psychoactive Drugs       Date:  2011 Jul-Sep

7.  A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.

Authors:  Katharine Cioe; Breanne E Biondi; Rebecca Easly; Amanda Simard; Xiao Zheng; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2020-09-22

8.  Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial.

Authors:  Stephen Magura; Joshua D Lee; Jason Hershberger; Herman Joseph; Lisa Marsch; Carol Shropshire; Andrew Rosenblum
Journal:  Drug Alcohol Depend       Date:  2008-10-18       Impact factor: 4.492

9.  Consistent adherence to guidelines improves opioid dependent patients' first year outcomes.

Authors:  Jodie A Trafton; Keith Humphreys; Alex H S Harris; Elizabeth Oliva
Journal:  J Behav Health Serv Res       Date:  2007-07-04       Impact factor: 1.505

10.  Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: rationale and design of the NAOMI study.

Authors:  Eugenia Oviedo-Joekes; Bohdan Nosyk; David C Marsh; Daphne Guh; Suzanne Brissette; Candice Gartry; Michael Krausz; Aslam Anis; Martin T Schechter
Journal:  Clin Trials       Date:  2009-06       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.